ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.
PUMD stock price ended at $0 on 水曜日, after rising NaN%
On the latest trading day Jan 07, 2026, the stock price of PUMD rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 24.8K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 200 shares were traded, amounting to a market value of approximately --.